LPCN - Lipocine Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
165
428
0
0
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
7,809
6,465
11,004
8,076
Selling General and Administrative
4,979
5,289
10,214
10,382
Total Operating Expenses
12,788
11,754
21,218
18,458
Operating Income or Loss
-12,623
-11,326
-21,218
-18,458
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
-
-334
236
-513
Income Before Tax
-12,940
-11,659
-20,982
-18,971
Income Tax Expense
1
1
1
1
Income from Continuing Operations
-12,941
-11,660
-20,983
-18,972
Net Income
-12,941
-11,660
-20,983
-18,972
Net Income available to common shareholders
-12,941
-11,660
-20,983
-18,972
Reported EPS
Basic
-
-0.55
-1.05
-1.04
Diluted
-
-0.55
-1.05
-1.04
Weighted average shares outstanding
Basic
-
21,352
20,052
18,258
Diluted
-
21,352
20,052
18,258
EBITDA
-
-11,307
-21,190
-18,426